The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy

Chiappa, Antonio; Makuuchi, Masatoshi; Lygidakis, N J; Zbar, Andrew P.; Chong, Geoffrey; Bertani, Emilio; Sitzler, P. J.; Biffi, R.; Pace, Ugo; Bianchi, Paolo Pietro; Contino, Gianmarco; Misitano, P.; Orsi, Franco; Travaini, Laura Lavinia; Trifirò, Giuseppe; Zampino, Maria Giulia; Fazio, Nicola; Goldhirsch, Aron; Andreoni, Bruno

doi:10.1016/j.critrevonc.2008.11.003

Cited by 33 publications

(24 citation statements)

References 149 publications

(168 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty to twenty-five percent (20-25%) of patients have clinically detectable colorectal-related liver metastases (CLM) at the initial diagnosis and approximately 50% of the patients develop CLM during their disease course (Garden et al, 2006). Resection of the CLM, sometimes in combination with other local treatment modalities, such as radiofrequency ablation (RFA), has become the standard of care, and offers the only potential for cure (Chiappa et al, 2009;Ksienski et al, 2010). The development of new surgical approaches, together with an increasing use of the perioperative systemic therapy, have led to an increase of the percentage of patients potentially eligible for curative liver resection (Rolfo et al, , 2013Bronte et al, 2015Bronte et al, , 2013.…”

Section: Introductionmentioning

confidence: 99%

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Passiglia

Bronte

Bazan

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Materials and methods: Data from all published studies reporting survival outcomes (RFS and/or OS) of CRC patients who received resection of CLM, stratified by KRAS and/or BRAF mutation status were collected, according to the PRISMA guidelines. Pooled HRs were calculated for both the OS and/or RFS. Results: Seven eligible trials (1403 patients) were included. Pooled analysis showed that KRAS mutations predicted a significantly worse both RFS (HR: 1.65; 95% CI: 1.23-2.21) and OS (HR: 1.86; 95% CI: 1.51-2.30) in patients who underwent surgical resection of CLM. BRAF mutations were also associated with a significantly worse OS (HR: 3.90; 95% CI: 1.96-7.73) in this subgroup of patients. Conclusions: This meta-analysis suggests both KRAS and BRAF mutations as poor, prognostic biomarkers, associated with worse survival outcomes, in patients undergoing hepatic resection of CLM

show abstract

Section: Introductionmentioning

confidence: 99%

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Passiglia

Bronte

Bazan

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…In 1960's and 1970's the major- ity of patients with CLM (70-80%) were never candidates for resection, but nowadays a large portion of patients undergo surgery due to significant improvements in preoperative investigations, surgical techniques, anesthesia, chemotherapy regimens and the expansion of resectability criteria. 4,5 Based on oncologic reasoning at that time, hemihepatectomies were considered the only curative option in patients with CLM. Nevertheless, over the years, PSLR has increasingly been used for CLM.…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic parenchyma-sparing liver resection for colorectal metastases

Pelanis

Kazaryan

Sahakyan

et al. 2018

HPB

View full text Add to dashboard Cite

Disclosure: No potential conflicts of interest were disclosed.Background. Laparoscopic liver resection (LLR) of colorectal liver metastases (CLM) is increasingly performed in specialized centers. While there is a trend towards a parenchyma-sparing strategy in multimodal treatment for CLM, its role is yet unclear. In this study we present short-and long-term outcomes of laparoscopic parenchyma-sparing liver resection (LPSLR) at a single center. Conclusions. LPSLR of CLM can be performed safely with the good surgical and oncological results. The technique facilitates repeated surgical treatment, which may improve survival for patients with CLM.

show abstract

“…Approximately 20% of patients will present with liver metastasis at the time of diagnosis, and another 25% will develop liver metastasis during the course of their disease [2]. Complete surgical resection remains the sole curative treatment for patients with metastatic disease limited to the liver [3], but the majority of patients (75-85%) with colorectal liver metastasis present with unresectable disease.…”

Section: Introductionmentioning

confidence: 99%

Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors

Ganepola

Mazziotta

Weeresinghe

et al. 2009

Clin Exp Metastasis

View full text Add to dashboard Cite

The objective of this study was to gain insights into the biological basis of the metastatic process by characterizing the gene expression differences between primary and metastatic colon cancers. Recent studies have demonstrated that few new mutational changes are acquired during the metastatic progression of colon tumors [Jones et al., Proc Natl Acad Sci USA 105 (11): 4283-4288, 2008]. However, the extent to which epigenetic and transcriptional changes occur between primary and metastatic colon cancer remains unknown. We approached these issues using Affymetrix microarrays to assess the similarities and differences in gene expression profiles between macro-dissected primary and metastatic colon tumors. Unexpectedly, we found that expression of a number of cell proliferation markers were reduced in the liver metastases of colon tumors when compared to primary tumors. This finding was validated by immunohistochemical staining of Ki67 and Cyclin D1 in Formalin-Fixed Paraffin-Embedded (FFPE) section of the same samples, and in an independent cohort of FFPE matched tumor and metastatic tissue samples. These results indicate that significant transcriptional differences exist between primary and metastatic colon tumors, and demonstrate that metastatic lesions have a lower proliferative rate compared to primary tumors. These findings may have implications for interpreting differences in response rates between primary and metastatic lesions and suggest that measurement of expression-based biomarkers in metastatic tissue will be most informative for understanding the basis of response of metastatic tumors to therapeutic intervention.

show abstract

The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy

Cited by 33 publications

References 149 publications

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Laparoscopic parenchyma-sparing liver resection for colorectal metastases

Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors

Contact Info

Product

Resources

About